Biogen INC BIOGEN INC ORD SHS | 303.79 / +1.43% |
Date/Time | 12/06 / 19:26 |
Chg. / Chg.(%) | 4.29 / +1.43% |
Bid | - |
Ask | - |
Open | 296.68 |
Previous Close | 299.50 |
High | 304.00 |
Low | 296.68 |
Volume [USD] | 457,834.91 |
Volume [Units] | 1,645 |
Price fixings | 23 |
ISIN | US09062X1037 |
Security | 0R1B |
Exchange | London International |
Type | Stock |
Other Exchanges
Exchange | Last | Volume | |
---|---|---|---|
Lang & Schwa.. | 270.850 | ![]() |
|
NASDAQ | 300.2600 | ![]() |
2,261,355 |
IEX | 300.34 | ![]() |
201,966 |
Cboe US | 300.28 | ![]() |
164,023 |
London Inter.. | 303.79 | ![]() |
1,645 |
TradeGate | 272.100 | ![]() |
780 |
Xetra | 273.30 | ![]() |
268 |
Stuttgart | 273.150 | ![]() |
202 |
Vienna Globa.. | 273.40 | ![]() |
133 |
Mexico | 5,860.00 | ![]() |
30 |
Frankfurt | 272.3500 | ![]() |
23 |
München | 268.45 | ![]() |
0 |
Hamburg | 268.50 | ![]() |
0 |
Düsseldorf | 270.00 | ![]() |
0 |
Berlin | 274.60 | ![]() |
0 |
Hannover | 268.50 | ![]() |
0 |
SIX Swiss Ex.. | 232.00 | ![]() |
|
gettex | 272.650 | ![]() |
News
- Biogen stocks rise on new Alzheimer drug breakthrough
12/05/2019 / 19:26 - TeleTrader - Biogen Announces Positive Phase 2 Study Results for Cutaneous Lupus Erythematosus (CLE) and Systemic Lupus Erythematosus (SLE)
12/03/2019 / 13:30 - GlobeNewswire - Biogen Presents Data Demonstrating Improved Gastrointestinal Tolerability With VUMERITY™ (diroximel fumarate) Compared to TECFIDERA® (dimethyl fumarate)
11/22/2019 / 13:30 - GlobeNewswire - Biogen Announces Enrollment Completion of Global Phase 3 Gene Therapy Study for an Inherited Retinal Disorder
11/21/2019 / 13:30 - GlobeNewswire - AZTherapies Announces Appointment of Ernest D. Penachio as Vice President of Manufacturing Operations and CMC
11/06/2019 / 22:05 - GlobeNewswire